Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6317990 | 0.78 | HDAC3 (0.54) | — | |
| SCHEMBL5450071 | 0.77 | CES1 (0.52) | — | |
| SCHEMBL7734069 | 0.75 | LMNA (0.46) | — | |
| SCHEMBL20319855 | 0.72 | KMT2A (0.58) | RORCPSIP1 | |
| SCHEMBL5759432 | 0.70 | RORC (0.59) | RORCPSIP1 | |
| Trifluoroacetic Acid SCHEMBL5758188 | 0.70 | PSIP1 (0.71) | RORCPSIP1 | |
| SCHEMBL28253979 | 0.69 | CYP2C9 (0.56) | RORCPSIP1 | |
| SCHEMBL20943253 | 0.69 | PSIP1 (0.59) | RORCPSIP1 | |
| SCHEMBL21616664 | 0.68 | RORC (0.53) | RORCPSIP1 | |
| SCHEMBL19777840 | 0.68 | CA12 (0.66) | RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1562902-B1 | 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | ASTRAZENECA AB (SE) | 2006-05-03 | — | — | EP | disclosed |
| US-20060035938-A1 | 2-Pyridone derivatives as inhibitors of neutrophile elastase | ASRAZENECA AB (SE) | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035938-A1 | 2-Pyridone derivatives as inhibitors of neutrophile elastase | SERPINB1, ELANE, SERPINE1 | RORC 3660/4885PSIP1 3665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.